Pharmaceutical Technology28 天
IL2-CD25 by Bristol-Myers Squibb for Systemic Lupus Erythematosus: Likelihood of Approval
IL2-CD25 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData, Phase I drugs for Systemic Lupus Erythematosus have a ...